Compositions and methods for modulating immune responses

a technology of immune response and composition, applied in the direction of depsipeptides, peptide/protein ingredients, fusion polypeptides, etc., can solve the problems of insufficient magnitude of immune response to many different antigens, which are often detectable, and cannot afford to protect against disease processes mediated by agents

Inactive Publication Date: 2007-03-08
ZYMOGENETICS INC
View PDF1 Cites 39 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, immune responses to many different antigens (e.g., microbial antigens or tumor antigens), while detectable, are frequently of insufficient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Murine zB7R1 Expression Construct

[0391] An expression plasmid containing a polynucleotide encoding the full-length mouse zB7R1 (SEQ ID NO:8) was constructed via homologous recombination. A fragment of mouse zB7R1 cDNA was isolated by PCR using the polynucleotide sequence as identified by SEQ ID NO:29 with flanking regions at the 5′ and 3′ ends corresponding to the vector sequences flanking the mouse zB7R1 insertion point using primers zc51280 (SEQ ID NO:30) and zc51314 (SEQ ID NO:31).

[0392] The PCR reaction mixture was run on a 2% agarose gel and a band corresponding to the size of the insert is gel-extracted using a QIAquick™ Gel Extraction Kit (Qiagen, Valencia, Calif.). Plasmid pZMP21 is a mammalian expression vector containing an expression cassette having the MPSV promoter, multiple restriction sites for insertion of coding sequences, a stop codon, an E. coli origin of replication; a mammalian selectable marker expression unit comprising an SV40 promoter, enhancer and origin ...

example 2

Mouse zB7R1mFc2pZMP21

[0395] An expression plasmid containing a polynucleotide encoding the extra-cellular domain of mouse zB7R1 and the mouse Fc2 portion can be constructed via homologous recombination. A DNA fragment of the extra-cellular domain of mouse zB7R1 is isolated by PCR using SEQ ID NO:32 with flanking regions at the 5′ and 3′ ends corresponding to the vector sequence and the mouse Fc2 sequence flanking the mouse zB7R1 insertion point using primers zc50437 (SEQ ID NO:33) and zc50438 (SEQ ID NO:34).

[0396] The PCR reaction mixture is run on a 2% agarose gel and a band corresponding to the size of the insert is gel-extracted using a QIAquick™ Gel Extraction Kit (Qiagen, Valencia, Calif.). The initial plasmid used is pZMP21 that used pZMP21 as a base vector and has the mouse Fc2 portion built into it. Plasmid pZMP21 is a mammalian expression vector containing an expression cassette having the MPSV promoter, multiple restriction sites for insertion of coding sequences, a stop...

example 3

B7 / mFc2 Expression Constructs

[0399] An expression vector, pZMP21 hB7R1 / mFc2 (SEQ ID NO: 68), was prepared to express a c-terminally Fc tagged soluble version of zB7R1. A 734 base pair fragment was generated by PCR containing the extracellular domain of zB7R1 (SEQ ID NO:3) and the first two amino acids of mFc (glutamine and proline) with EcoRI and BglII sites coded on the 5′ and 3′ ends, respectively.

[0400] This PCR fragment was generated using primers zc48914 (SEQ ID NO:35) and zc48908 (SEQ ID NO:36) by amplification from a human placenta cDNA library. The PCR reaction conditions were as follows: 25 cycles of 94° C. for 1 minute, 60° C. for 1 minute, and 72° C. for 2 minutes; 1 cycle at 72° C. for 10 minutes; followed by a 4° C. soak. A 699 base pair fragment was generated by PCR containing the constant 2 and constant 3 domains of effector function minus BALB-C IgG gamma 2a (mFc2). This PCR fragment was generated using primers zc48911 and ac48915 by amplification from an expressio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Description

REFERENCE TO RELATED INVENTIONS [0001] This application claims the benefit of U.S. Provisional Application Ser. No. 60 / 680,374, filed May 12, 2005, U.S. Provisional Application Ser. No. 60 / 791,626, filed Apr. 13, 2006, and U.S. Provisional Application Ser. No. 60 / 795,005, filed Apr. 26, 2006 all of which are incorporated in their entirety herein by reference.BACKGROUND OF THE INVENTION [0002] Positive and negative costimulatory signals play critical roles in the modulation of T cell activity, and the molecules that mediate these signals have proven to be effective targets for immunomodulatory agents. Positive costimulation, in addition to T cell receptor (TCR) engagement, is required for optimal activation of naive T cells, whereas negative costimulation is believed to be required for the acquisition of immunologic tolerance to self, as well as the termination of effector T cell functions. Upon interaction with B7-1 or B7-2 on the surface of antigen-presenting cells (APC), CD28, the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12P21/06C07H21/04C07K14/705C07K16/30
CPCA61K38/00C07K14/70532C07K16/2818C07K16/2827C07K2317/34C07K2319/00C07K2319/30G01N33/505C07K2316/96C07K2317/73C07K2317/75A61P1/04A61P1/12A61P29/00A61P35/00A61P37/00A61P37/02A61P37/06A61P43/00A61K39/3955C07K14/47C12Q1/66A61K2039/507C07K16/2803C07K2317/76G01N33/56972G01N2333/70532
Inventor GAO, ZERENLEVIN, STEVEN D.BILSBOROUGH, JANINEWEST, JAMES W.BRANDT, CAMERON S.RAMSDELL, FREDERICK J.HOWARD, EDWARD D.CHADWICK, ERICK M.
Owner ZYMOGENETICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap